| ACR | American College of Rheumatology |
| AE/AEs | Adverse Event(s) |
| ANA | Antinuclear Antibody |
| AUC | Area Under the (plasma) Concentration–Time Curve |
| BID | Twice Daily |
| CI | Confidence Interval(s) |
| CMC | Carboxymethylcellulose |
| Cmax | Maximum (plasma) Concentration |
| DEWS | Dry Eye Workshop |
| EULAR | European Alliance of Associations for Rheumatology |
| GCP | Good Clinical Practice |
| IgA | Immunoglobulin A |
| IgG | Immunoglobulin G |
| IRB | Institutional Review Board |
| KGCP | Korean Good Clinical Practice |
| MAD | Multiple Ascending Dose |
| MedDRA | Medical Dictionary for Regulatory Activities |
| MFDS | Ministry of Food and Drug Safety (Republic of Korea) |
| OSS | Ocular Surface Staining |
| pSS | Primary Sjögren’s Syndrome |
| PK | Pharmacokinetics |
| PT | Preferred Term (MedDRA term level) |
| RF | Rheumatoid Factor |
| RF-IgA | IgA Isotype of Rheumatoid Factor |
| SD | Standard Deviation |
| SjS | Sjögren’s Syndrome |
| SOC | System Organ Class |
| SPEED | Standard Patient Evaluation of Eye Dryness |
| SSA | Anti-Ro (SSA) Antibody |
| SSB | Anti-La (SSB) Antibody |
| TBUT | Tear Break-Up Time |
| TID | Three Times Daily |
| XI | Xerostomia Inventory |